Trial | Treatment arms | Overall survival | Progression-free survival or TTP or FFS | ||||
---|---|---|---|---|---|---|---|
 |  | N | Median (mo) | Statistical comparison | N | Median (mo) | Statistical comparison |
Carducci, 2004 [85] | Atrasentan | NR | 408 | NR | HR for TTP = 1.14 (95% CI, 0.98–1.34) p = 0.091 | ||
 | placebo |  |  |  | 401 |  |  |
Carducci, 2003 [79] | atrasentan 10 mg | NR | 89 | 6.5 | p = 0.13 (TTP) | ||
 | atrasentan 2.5 mg |  |  |  | 95 | 6.4 | p = 0.29 (TTP) |
 | placebo |  |  |  | 104 | 4.9 | NA |
Small, 2003 [86] | APC8015 | NR | 82 | NR | HR for TTP = 1.39 (95% CI, 0.95–2.04) p = 0.085 | ||
 | placebo |  |  |  | 45 |  |  |
Small, 2002 [81] | suramin (3.192 g/m2) | 128 | 16 | p = 0.49 | 128 | NR | p = NS |
 | suramin (5.320 g/m2) | 124 | 14 |  | 124 |  |  |
 | suramin (7.661 g/m2) | 120 | 13 |  | 120 |  |  |
Ahmann, 2001 [87] | prinomastat (5 mg) mitoxantrone prednisone | 134 | 15.1 | p = NS | 134 | 6 | p = NS |
 | prinomastat (10 mg) mitoxantrone prednisone | 134 | 14.7 |  | 134 | 4.7 |  |
 | mitoxantrone prednisone placebo | 138 | 14.8 |  | 138 | 6 |  |
Small, 2000 [82] | suramin hydrocortisone | 228 | 10.2 | p = NS | 228 | NR | RR for TTP = 1.51 (95% CI, 1.22–1.85) p = 0.0003 |
 | placebo hydrocortisone | 230 | 10 |  | 230 |  |  |
Debruyne, 1998 [83] | liarozole | 160 | 10.3 | p = 0.52 HR = 0.74* (95% CI, 0.56–0.99) p = 0.039 | 160 | 4.9 | p = NS |
 | CPA | 161 | 10.3 |  | 161 | 4.6 |  |